title: Re: activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
authors.affiliation: Department of Urology, Skåne University Hospital Malmö, Malmö, Sweden; Department of Clinical Sciences Malmö, Division of Urological Cancers, Lund University, Lund, Sweden. Electronic address: anders.bjartell@med.lu.se.
authors.forename: Anders
authors.initials: A
authors.lastname: Bjartell
mesh_terms: D059002:Androgen Receptor Antagonists / Q000494:pharmacology*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality*
chemical_list: D059002:Androgen Receptor Antagonists; D017430:Prostate-Specific Antigen